Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 5, 9, 1, 13, 7 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Ankylosing Spondylitis (Bekhterev's Disease) - Overview
  3. Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Adello Biologics LLC
  • Allergan Plc
  • Alteogen Inc
  • Amgen Inc
  • Biocad
  • Biocon Ltd
  • Bionovis SA
  • Celgene Corp
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novartis AG
  • Oncobiologics Inc
  • Protalix BioTherapeutics Inc
  • Reliance Life Sciences Pvt Ltd
  • Sandoz International GmbH
  • Shanghai Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA
  • Xbrane Biopharma AB

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.